According to the American Cancer Institute, cancer is the second leading cause of death in the United States. Half of all men and one-third of all women in the U.S. will develop cancer during their lifetimes. Today, millions of people are living with cancer or have had cancer.
As the world’s population continues to age, cancer treatment will likely become one of the single largest health care expenditures in the U.S. and other industrialized nations.
The Company’s initial strategy is to expand and enhance clinical applications of at least seven widely used chemotherapy drugs (5-Fluorouracil, Irinotecan, Doxorubicin, Paclitaxel, Oxaliplatin, Cyclophosphamide, and Cisplatin) by combining them with DAVANAT®, our carbohydrate-based compound. The Company plans to leverage its carbohydrate compounds by applying them to other FDA-approved drugs, including drugs for conditions or ailments other than cancer, that would benefit from reduced toxicity and/or greater efficacy. This strategy should enable the Company to expand the portfolio of drugs to which we may apply our technology. The objective is to obtain FDA approval for our “Glyco-Upgrade” ™ compounds, and to negotiate license agreements with pharmaceutical and/or biotech companies with regards to the manufacturing and marketing of its drugs.